Preventing aggressive prostate cancer with proven cardiovascular disease preventive methods

Asian Journal of Andrology

Volumn 17, Issue 6, 2015, Pages 874-877

  Moyad, Mark A ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN; MULTIVITAMIN; ANTIDIABETIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT;

ARTICLE; CANCER PREVENTION; CANCER RISK; CARDIOVASCULAR DISEASE; CLINICAL TRIAL (TOPIC); DIET SUPPLEMENTATION; HUMAN; HYPERTENSION; LIFESTYLE MODIFICATION; MALE; PROSTATE CANCER; CARDIOVASCULAR DISEASES; DYSLIPIDEMIAS; GLUCOSE INTOLERANCE; METABOLIC SYNDROME X; OBESITY; PATHOLOGY; PROSTATIC NEOPLASMS; RISK FACTOR; RISK REDUCTION; SEDENTARY LIFESTYLE;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; CARDIOVASCULAR DISEASES; DYSLIPIDEMIAS; GLUCOSE INTOLERANCE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOGLYCEMIC AGENTS; MALE; METABOLIC SYNDROME X; METFORMIN; OBESITY; PROSTATIC NEOPLASMS; RISK FACTORS; RISK REDUCTION BEHAVIOR; SEDENTARY LIFESTYLE;

EID: 84946225849     PISSN: 1008682X     EISSN: 17457262     Source Type: Journal    
DOI: 10.4103/1008-682X.156854     Document Type: Article

References (63)

1. Moyad MA. Complementary and Alternative Medicine for Prostate and Urologic Health. New York: Springer Publishing; 2014.
2. Lloyd?Jones D, Adams RJ, Brown TM, Carnethon M, et al. Heart disease and stroke statistics?2010 update: a report from the American Heart Association. Circulation 2010; 121: e46-215.
3. Bonow RO, Smaha LA, Smith SC Jr, Mensah GA, Lenfant C. World Heart Day 2002: the international burden of cardiovascular disease: responding to the emerging global epidemic. Circulation 2002; 106: 1602-5.
4. Eyre H, Kahn R, Robertson RM, Clark NG, Doyle C, et al. Preventing cancer, cardiovascular disease, and diabetes: a common agenda for the American Cancer Society, the American Diabetes Association, and the American Heart Association. Circulation 2004; 109: 3244-55.
5. Huncharek M, Haddock KS, Reid R, Kupelnick B. Smoking as a risk factor for prostate cancer: a meta?analysis of 24 prospective cohort studies. Am J Public Health 2010; 100: 693-701.
6. Zu K, Giovannucci E. Smoking and aggressive prostate cancer: a review of the epidemiologic evidence. Cancer Causes Control 2009; 20: 1799-810.
7. Kenfield SA, Stampfer MJ, Chan JM, Giovannucci E. Smoking and prostate cancer survival and recurrence. JAMA 2011; 305: 2548-55.
8. Cao Y, Ma J. Body mass index, prostate cancer?specific mortality, and biochemical recurrence: a systematic review and meta?analysis. Cancer Prev Res (Phila) 2011; 4: 486-501.
9. Joshu CE, Mondul AM, Menke A, Meinhold C, Han M, et al. Weight gain is associated with an increased risk of prostate cancer recurrence after prostatectomy in the PSA era. Cancer Prev Res (Phila) 2011; 4: 544-51.
10. Discacciati A, Orsini N, Wolk A. Body mass index and incidence of localized and advanced prostate cancer-A dose?response meta?analysis of prospective studies. Ann Oncol 2012; 23: 1665-71.
11. Wo o d a r d G, A hmed S, P o d e l s k i V, Hernandez?Boussard T, Presti J Jr, et al. Effect of Roux?en?Y gastric bypass on testosterone and prostate?specific antigen. Br J Surg 2012; 99: 693-8.
12. Kenfield SA, Stampfer MJ, Giovannucci E, Chan JM. Physical activity and survival after prostate cancer diagnosis in the health professionals follow?up study. J Clin Oncol 2011; 29: 726-32.
13. Oliveria SA, Lee IM. Is exercise beneficial in the prevention of prostate cancer? Sports Med 1997; 23: 271-8.
14. Torti DC, Matheson GO. Exercise and prostate cancer. Sports Med 2004; 34: 363-9.
15. Young?McCaughan S. Potential for prostate cancer prevention through physical activity. World J Urol 2012; 30: 167-79.
16. Bhaskaran K, Douglas I, Evans S, van Staa T, Smeeth L. Angiotensin receptor blockers and risk of cancer: cohort study among people receiving antihypertensive drugs in UK General Practice Research Database. BMJ 2012; 344: e2697.
17. De Nunzio C, Aronson W, Freedland SJ, Giovannucci E, Parsons JK. The correlation between metabolic syndrome and prostatic diseases. Eur Urol 2012; 61: 560-70.
18. Loeb S, Gupta A, Losonczy L, Tosoian J, Walsh PC. Does benign prostatic hyperplasia treatment with alpha?blockers affect prostate cancer risk? Curr Opin Urol 2013; 23: 2-4.
19. Roehrborn CG. BPH progression: concept and key learning from MTOPS, ALTESS, COMBAT, and ALF?ONE. BJU Int 2008; 101 Suppl 3: 17-21.
20. Siervo M, Lara J, Chowdhury S, Ashor A, Oggioni C, et al. Effects of the Dietary Approach to Stop Hypertension (DASH) diet on cardiovascular risk factors: a systematic review and meta?analysis. Br J Nutr 2014. [Epub ahead of print].
21. Saneei P, Salehi?Abargouei A, Esmaillzadeh A, Azadbakht L. Influence of Dietary Approaches to Stop Hypertension (DASH) diet on blood pressure: a systematic review and meta?analysis on randomized controlled trials. Nutr Metab Cardiovasc Dis 2014; 24: 1253-61.
22. Lawson KA, Wright ME, Subar A, Mouw T, Hollenbeck A, et al. Multivitamin use and risk of prostate cancer in the National Institutes of Health?AARP Diet and Health Study. J Natl Cancer Inst 2007; 99: 754-64.
23. Stevens VL, McCullough ML, Diver WR, Rodriguez C, Jacobs EJ, et al. Use of multivitamins and prostate cancer mortality in a large cohort of US men. Cancer Causes Control 2005; 16: 643-50.
24. Neuhouser ML, Barnett MJ, Kristal AR, Ambrosone CB, King IB, et al. Dietary supplement use and prostate cancer risk in the Carotene and Retinol Efficacy Trial. Cancer Epidemiol Biomarkers Prev 2009; 18: 2202-6.
25. Leitzmann MF, Stampfer MJ, Wu K, Colditz GA, Willett WC, et al. Zinc supplement use and risk of prostate cancer. J Natl Cancer Inst 2003; 95: 1004-7.
26. Wien TN, Pike E, Wisløff T, Staff A, Smeland S, et al. Cancer risk with folic acid supplements: a systematic review and meta?analysis. BMJ Open 2012; 2: e000653.
27. Clarke R, Halsey J, Lewington S, Lonn E, Armitage J, et al. Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause?specific mortality: meta?analysis of 8 randomized trials involving 37 485 individuals. Arch Intern Med 2010; 170: 1622-31.
28. Collin SM, Metcalfe C, Refsum H, Lewis SJ, Zuccolo L, et al. Circulating folate, vitamin B12, homocysteine, vitamin B12 transport proteins, and risk of prostate cancer: a case?control study, systematic review, and meta?analysis. Cancer Epidemiol Biomarkers Prev 2010; 19: 1632-42.
29. Gaziano JM, Sesso HD, Christen WG, Bubes V, Smith JP, et al. Multivitamins in the prevention of cancer in men: the Physicians' Health Study II randomized controlled trial. JAMA 2012; 308: 1871-80.
30. Sesso HD, Christen WG, Bubes V, Smith JP, MacFadyen J, et al. Multivitamins in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial. JAMA 2012; 308: 1751-60.
31. Christen WG, Glynn RJ, Manson JE, MacFadyen J, Bubes V, et al. Effects of multivitamin supplement on cataract and age?related macular degeneration in a randomized trial of male physicians. Ophthalmology 2014; 121: 525-34.
32. Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2009; 301: 39-51.
33. Klein EA, Thompson IM Jr, Tangen CM, Crowley JJ, Lucia MS, et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2011; 306: 1549-56.
34. Kristal AR, Darke AK, Morris JS, Tangen CM, Goodman PJ, et al. Baseline selenium status and effects of selenium and vitamin e supplementation on prostate cancer risk. J Natl Cancer Inst 2014; 106: djt456.
35. Barnett CM, Nielson CM, Shannon J, Chan JM, Shikany JM, et al. Serum 25?OH vitamin D levels and risk of developing prostate cancer in older men. Cancer Causes Control 2010; 21: 1297-303.
36. Chung M, Lee J, Terasawa T, Lau J, Trikalinos TA. Vitamin D with or without calcium supplementation for prevention of cancer and fractures: an updated meta?analysis for the U.S. Preventive Services Task Force. Ann Intern Med 2011; 155: 827-38.
37. Isenor JE, Ensom MH. Is there a role for therapeutic drug monitoring of vitamin D level as a surrogate marker for fracture risk? Pharmacotherapy 2010; 30: 254-64.
38. Ross AC, Taylor CL, Yaktine AL, Del Valle HB, editors. Institute of Medicine of the National Academies. Dietary Reference Intakes for Calcium and Vitamin D. Washington, DC: National Academies Press; 2011.
39. Ardawi MS, Sibiany AM, Bakhsh TM, Qari MH, Maimani AA. High prevalence of vitamin D deficiency among healthy Saudi Arabian men: relationship to bone mineral density, parathyroid hormone, bone turnover markers, and lifestyle factors. Osteoporos Int 2012; 23: 675-86.
40. Jääskeläinen T, Knekt P, Marniemi J, Sares?Jäske L, Männistö S, et al. Vitamin D status is associated with sociodemographic factors, lifestyle and metabolic health. Eur J Nutr 2013; 52: 513-25.
41. Kotani K, Sekine Y, Ishikawa S, Ikpot IZ, Suzuki K, et al. High?density lipoprotein and prostate cancer: an overview. J Epidemiol 2013; 23: 313-9.
42. Platz EA, Till C, Goodman PJ, Parnes HL, Figg WD, et al. Men with low serum cholesterol have a lower risk of high?grade prostate cancer in the placebo arm of the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev 2009; 18: 2807-13.
43. Thomas JA 2nd, Gerber L, Bañez LL, Moreira DM, Rittmaster RS, et al. Prostate cancer risk in men with baseline history of coronary artery disease: results from the REDUCE Study. Cancer Epidemiol Biomarkers Prev 2012; 21: 576-81.
44. Murtola TJ, Visakorpi T, Lahtela J, Syvälä H, Tammela TLj. Statins and prostate cancer prevention: where we are now, and future directions. Nat Clin Pract Urol 2008; 5: 376-87.
45. Crosara Teixeira M, Braghiroli MI, Sabbaga J, Hoff PM. Primary prevention of colorectal cancer: myth or reality? World J Gastroenterol 2014; 20: 15060-9.
46. Sostres C, Gargallo CJ, Lanas A. Aspirin, cyclooxygenase inhibition and colorectal cancer. World J Gastrointest Pharmacol Ther 2014; 5: 40-9.
47. Shebl FM, Sakoda LC, Black A, Koshiol J, Andriole GL, et al. Aspirin but not ibuprofen use is associated with reduced risk of prostate cancer: a PLCO study. Br J Cancer 2012; 107: 207-14.
48. Bosetti C, Rosato V, Gallus S, Cuzick J, La Vecchia C. Aspirin and cancer risk: a quantitative review to 2011. Ann Oncol 2012; 23: 1403-15.
49. Rothwell PM, Fowkes FG, Belch JF, Ogawa H, Warlow CP, et al. Effect of daily aspirin on long?term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 2011; 377: 31-41.
50. Mahmud S, Franco E, Aprikian A. Prostate cancer and use of nonsteroidal anti?inflammatory drugs: systematic review and meta?analysis. Br J Cancer 2004; 90: 93-9.
51. Choe KS, Cowan JE, Chan JM, Carroll PR, D'Amico AV, et al. Aspirin use and the risk of prostate cancer mortality in men treated with prostatectomy or radiotherapy. J Clin Oncol 2012; 30: 3540-5.
52. Jacobs EJ, Newton CC, Stevens VL, Campbell PT, Freedland SJ, et al. Daily aspirin use and prostate cancer?specific mortality in a large cohort of men with nonmetastatic prostate cancer. J Clin Oncol 2014; 32: 3716-22.
53. Bosetti C, Rosato V, Gallus S, La Vecchia C. Aspirin and prostate cancer prevention. Recent Results Cancer Res 2014; 202: 93-100.
54. Vi d a l AC, Howard L E , M o r e i r a DM, Castro?Santamaria R, Andriole GL, et al. Aspirin, NSAIDs, and risk of prostate cancer: results from the REDUCE study. Clin Cancer Res 2015; 21: 756-62.
55. Jalving M, Gietema JA, Lefrandt JD, de Jong S, Reyners AK, et al. Metformin: taking away the candy for cancer? Eur J Cancer 2010; 46: 2369-80.
56. Rothermundt C, Hayoz S, Templeton AJ, Winterhalder R, Strebel RT, et al. Metformin in chemotherapy?naive castration?resistant prostate cancer: a multicenter phase 2 trial (SAKK 08/09). Eur Urol 2014; 66: 468-74.
57. Nobes JP, Langley SE, Klopper T, Russell?Jones D, Laing RW. A prospective, randomized pilot study evaluating the effects of metformin and lifestyle intervention on patients with prostate cancer receiving androgen deprivation therapy. BJU Int 2012; 109: 1495-502.
58. Clements A, Gao B, Yeap SH, Wong MK, Ali SS, et al. Metformin in prostate cancer: two for the price of one. Ann Oncol 2011; 22: 2556-60.
59. Colquhoun AJ, Venier NA, Vandersluis AD, Besla R, Sugar LM, et al. Metformin enhances the antiproliferative and apoptotic effect of bicalutamide in prostate cancer. Prostate Cancer Prostatic Dis 2012; 15: 346-52.
60. Babcook MA, Sramkoski RM, Fujioka H, Daneshgari F, Almasan A, et al. Combination simvastatin and metformin induces G1?phase cell cycle arrest and Ripk1? and Ripk3?dependent necrosis in C4?2B osseous metastatic castration?resistant prostate cancer cells. Cell Death Dis 2014; 5: e1536.
61. Kirby RS, Kirby M. The urologist as an advocate of men's health: 10 suggested steps toward helping patients achieve better overall health. Urology 2005; 66 5 Suppl: 52-6.
62. Goldenberg SL, White A. Male health-a recent paradigm. Nat Rev Urol 2015; 12: 15-16.
63. Moyad MA. Promoting Wellness: for Prostate Cancer Patients. 4th ed. Ann Arbor, MI: Spry Publishing LLC; 2013.